Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial

UPRISE (Urine Prostate Screening Integrated With MRI for Prostate Cancer Early Detection)

This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.

Inclusion Criteria:

• Males aged 50-75
• PSA 3-20 ng/ml within the previous 3 months
• Fit to undergo all procedures listed in protocol per treating physician's discretion
• No prostate biopsy in the past 4 years
• No prostate MRI in the past 2 years
• Able to provide written informed consent

Exclusion Criteria:

• Prior diagnosis of prostate cancer
• Contraindication to MRI (e.g. claustrophobia, pacemaker)
• Contraindication to prostate biopsy
• Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work